Form 4: Verve Therapeutics CFO Allison Dorval Executes Stock Transactions
SEC Form 4 Filing
Verve Therapeutics' Chief Financial Officer, Allison Dorval, recently executed transactions involving the company's stock, including the vesting of restricted stock units and a subsequent sale to cover tax obligations.
Summary
- Allison Dorval, the Chief Financial Officer of Verve Therapeutics, engaged in stock transactions.
- On November 29, 2024, 1,875 restricted stock units (RSUs) vested and were converted into common stock.
- On December 2, 2024, 555 shares of common stock were sold at a price of $5.64 per share.
- The sale of shares was to cover withholding tax liabilities associated with the vesting of the RSUs.
- These transactions were part of a pre-arranged automatic sale plan adopted by Ms. Dorval on December 9, 2021.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and does not indicate any positive or negative sentiment.
Positives
- The vesting of RSUs indicates that performance milestones were likely met.
- The automatic sale plan ensures compliance and avoids discretionary trading concerns.
Industry Context
This is a routine filing related to stock transactions by a company executive, which is common in publicly traded companies. It does not indicate any specific industry trend.
Comparison to Industry Standards
- The vesting and sale of shares by executives is a standard practice across publicly traded companies, particularly in the biotech sector.
- Many companies use similar automatic sale plans to manage tax obligations related to equity compensation.
- The number of shares and the sale price are not unusual for a CFO of a company of this size.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they are routine and do not indicate any change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 2021-11-29 | Allison Dorval was granted 7,500 RSUs. |
| 2021-12-09 | Allison Dorval adopted a durable automatic sale instruction plan. |
| 2024-11-29 | 1,875 RSUs vested and converted to common stock. |
| 2024-12-02 | 555 shares of common stock were sold at $5.64 per share. |
| 2024-12-03 | Form 4 filing date. |
Keywords
Verve Therapeutics, Allison Dorval, stock transactions, restricted stock units, RSUs, insider trading, SEC Form 4, vesting, automatic sale plan, tax liability
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.